Zárate A, Morán C, Hernández M, Ochoa R

Language: Spanish
References: 15
Page: 165-174
PDF size: 237.01 Kb.

ABSTRACT

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders, affecting nearly 20 % of women of reproductive age. Recently, it has been recognized that in addition to endocrine abnormalities, many patients with PCOS demonstrate metabolic aberrations. Most significant is the presence of insulin resistance. Insulin resistance leads to development of compensatory hyperinsulinemia, and this hyperinsulinemia plays a role in the pathogenesis of hyperandrogenism. The treatment for PCOS depends primarily on symptoms exhibited by patients and whether infertility is an issue. For women not interested in becoming pregnant, oral contraceptives are effective at providing regular menses and reducing androgen levels. Among therapy options for symptoms are antiandrogen agents for hirsutism and acne, and fertility treatment with ovulation-inducing agents. Insulin-reducing or sensitizing agents including metformin and troglitazone have improved clinical symptoms and metabolic disturbances in many patients. Treatment goals includes identification and prevention of potential cardiovascular risks, ongoing pharmacologic research focusing on treatment of insulin resistance, and dyslipoproteinemia appears promising in reversing long-term complications of the syndrome.

REFERENCES

1. 1. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-191.

2. 2. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-861.

3. 3. Zárate A, Hernández M. Síndrome de ovarios poliquísticos: una entidad sistémica metabólica. Rev Med UNAM 1997;40:230-233.

4. 4. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980;50:113-116.

5. 5. Hunter MH, Sterret JJ. Polycystic ovary syndrome: It’s not just infertility. Am Family Phys 2000;12: 456-459.

6. 6. Hamburg R. Polycystic ovary syndrome-from gynecological curiosity to multisystem endo-crinopathology. Hum Reprod 1996;10:29-39.

7. 7. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanisms and implications for pathogenesis. Endocr Rev 1997;18:774-800.

8. 8. Polson DW, Adams J, Wadsworth J, Farnks S. Polycystic ovaries, a common finding in normal women. Lancet 1988;1:870-872.

9. 9. Swanson M, Sauerbrie EJ, Cooperberg PL. Medical implications of ultrasonically detected polycystic ovaries. J Clin Ultrasound 1981;9:219-222.

10. Pierport T, Mckeique PM, Isaacs AJ, Jacobs HS. Mortality of women with polycystic ovary syn-drome at long term follow-up. J Clin Epidemiol 1998;51:581-586.

11. Bachmann GA. Polycystic ovary syndrome: Meta-bolic challenges and new treatment options. Am J Obstet Gynecol 1998;179:87-88.

12. Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone F, Caputo M, Muggeo M, Castello R. Comparison of spirolactone, flutamide, and finas-teride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2000;85:89-94.

13. Velázquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, by hyperandrogenemia, and systolic blood pressure facilitating normal menses and pregnancy. Metabolism 1994;43:647-654.

14. Nestler JE Jakubowicz DJ. Decreases in ovarian cytochrome P450c 17 activity and serum free testosterone after reduction in insulin secretion in women with polycystic ovary syndrome. N Engl J Med 1996;335: 617-2

15. Zárate A, Hernández M, Fonseca M, Ochoa R. Empleo de metformin en el manejo de adolescentes con el síndrome de ovarios poliquísticos. Ginec Obstet Mex 1997;65:504-508.